Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Michael Kosteljanetz"'
Autor:
Thomas Urup, Signe Regner Michaelsen, Lars Rønn Olsen, Anders Toft, Ib Jarle Christensen, Kirsten Grunnet, Ole Winther, Helle Broholm, Michael Kosteljanetz, Shohreh Issazadeh-Navikas, Hans Skovgaard Poulsen, Ulrik Lassen
Publikováno v:
Molecular Oncology, Vol 10, Iss 8, Pp 1160-1168 (2016)
Background Bevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study w
Externí odkaz:
https://doaj.org/article/bd720aa45e524484b30672fdd8de1366
Autor:
Hans Skovgaard Poulsen, Kirsten Grunnet, Ulrik Lassen, Vibeke Andrée Larsen, Thomas Urup, Ib Jarle Christensen, Helle Broholm, Michael Kosteljanetz, Babloo Lukram, Signe Regner Michaelsen, Anders Toft
Publikováno v:
Cancer Investigation. 36:165-174
Predictive biomarkers and prognostic models are required to identify recurrent grade III glioma patients who benefit from existing treatment. In this study of 62 recurrent grade III glioma patients, a range of clinical and paraclinical factors are te
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f836cdaa566accd6b334c5c1ea86369
https://doi.org/10.1080/07357907.2018.1430818
https://doi.org/10.1080/07357907.2018.1430818
Autor:
René Johannes Laursen, Steinbjørn Hansen, Michael Kosteljanetz, Birthe Krogh Rasmussen, Bente Mertz Nørgård, Kim Oren Gradel, Rikke Guldberg, Henrik Schultz
Publikováno v:
Hansen, S, Rasmussen, B K, Laursen, R J, Kosteljanetz, M, Schultz, H, Nørgård, B M, Guldberg, R & Gradel, K O 2018, ' Treatment and survival of glioblastoma patients in Denmark : The Danish Neuro-Oncology Registry 2009-2014 ', Journal of Neuro-Oncology, vol. 139, no. 2, pp. 479-489 . https://doi.org/10.1007/s11060-018-2892-7
Hansen, S, Rasmussen, B K, Laursen, R J, Kosteljanetz, M, Schultz, H, Nørgård, B M, Guldberg, R & Gradel, K O 2018, ' Treatment and survival of glioblastoma patients in Denmark : The Danish Neuro-Oncology Registry 2009–2014 ', Journal of Neuro-Oncology, vol. 139, no. 2, pp. 479–489 . https://doi.org/10.1007/s11060-018-2892-7
Hansen, S, Rasmussen, B K, Laursen, R J, Kosteljanetz, M, Schultz, H, Nørgård, B M, Guldberg, R & Gradel, K O 2018, ' Treatment and survival of glioblastoma patients in Denmark : The Danish Neuro-Oncology Registry 2009–2014 ', Journal of Neuro-Oncology, vol. 139, no. 2, pp. 479-489 . https://doi.org/10.1007/s11060-018-2892-7
Hansen, S, Rasmussen, B K, Laursen, R J, Kosteljanetz, M, Schultz, H, Nørgård, B M, Guldberg, R & Gradel, K O 2018, ' Treatment and survival of glioblastoma patients in Denmark : The Danish Neuro-Oncology Registry 2009–2014 ', Journal of Neuro-Oncology, vol. 139, no. 2, pp. 479–489 . https://doi.org/10.1007/s11060-018-2892-7
Hansen, S, Rasmussen, B K, Laursen, R J, Kosteljanetz, M, Schultz, H, Nørgård, B M, Guldberg, R & Gradel, K O 2018, ' Treatment and survival of glioblastoma patients in Denmark : The Danish Neuro-Oncology Registry 2009–2014 ', Journal of Neuro-Oncology, vol. 139, no. 2, pp. 479-489 . https://doi.org/10.1007/s11060-018-2892-7
BACKGROUND: As many glioblastoma patients are in a poor condition they are unable to undergo the full treatment documented in clinical trials. We aimed to examine the survival and its relationship to clinical characteristics and treatment in a nation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f9fc46f10125b377038e71ab2f9f5fa
https://vbn.aau.dk/da/publications/d941610a-0c4b-497d-9e41-7b116a80ea4b
https://vbn.aau.dk/da/publications/d941610a-0c4b-497d-9e41-7b116a80ea4b
Autor:
Bente Mertz Nørgård, Rikke Guldberg, Michael Kosteljanetz, Kim Oren Gradel, Birthe Krogh Rasmussen, Steinbjørn Hansen, René Johannes Laursen, Henrik Schultz
Publikováno v:
Rasmussen, B K, Hansen, S, Laursen, R J, Kosteljanetz, M, Schultz, H, Nørgård, B M, Guldberg, R & Gradel, K O 2017, ' Epidemiology of glioma : clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry ', Journal of Neuro-Oncology, vol. 135, no. 3, pp. 571-579 . https://doi.org/10.1007/s11060-017-2607-5
Rasmussen, B K, Hansen, S, Laursen, R J, Kosteljanetz, M, Schultz, H, Norgard, B M, Guldberg, R & Gradel, K O 2017, ' Epidemiology of glioma : clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry ', Journal of Neuro-Oncology, vol. 135, no. 3, pp. 571-579 . https://doi.org/10.1007/s11060-017-2607-5
Rasmussen, B K, Hansen, S, Laursen, R J, Kosteljanetz, M, Schultz, H, Nørgård, B M, Guldberg, R & Gradel, K O 2017, ' Epidemiology of glioma : clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry ', Journal of Neuro-Oncology, vol. 135, no. 3, pp. 571–579 . https://doi.org/10.1007/s11060-017-2607-5
Rasmussen, B K, Hansen, S, Laursen, R J, Kosteljanetz, M, Schultz, H, Norgard, B M, Guldberg, R & Gradel, K O 2017, ' Epidemiology of glioma : clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry ', Journal of Neuro-Oncology, vol. 135, no. 3, pp. 571-579 . https://doi.org/10.1007/s11060-017-2607-5
Rasmussen, B K, Hansen, S, Laursen, R J, Kosteljanetz, M, Schultz, H, Nørgård, B M, Guldberg, R & Gradel, K O 2017, ' Epidemiology of glioma : clinical characteristics, symptoms, and predictors of glioma patients grade I-IV in the the Danish Neuro-Oncology Registry ', Journal of Neuro-Oncology, vol. 135, no. 3, pp. 571–579 . https://doi.org/10.1007/s11060-017-2607-5
In this national population-based study of glioma, we present epidemiologic data on incidence, demographics, survival, clinical characteristics and symptoms, and evaluate the association of specific indicators with the grade of glioma. We included 19
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e19d6d8cbfc71adedc0a9161f1f086c
https://pubmed.ncbi.nlm.nih.gov/28861666
https://pubmed.ncbi.nlm.nih.gov/28861666
Autor:
Carsten E. Thomsen, Marie Luise Bisgaard, Michael Kosteljanetz, Marie Louise Mølgaard Binderup, Steen Gimsing
Publikováno v:
International Journal of Audiology. 52:771-775
Endolymphatic sac tumours (ELSTs) of the inner ear occur in 16% of patients with the hereditary tumor syndrome von Hippel-Lindau disease (vHL). ELSTs of all sizes can cause irreversible hearing loss which can, however, be prevented through early diag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e4a240d6fd375f34d11213171bf7990
https://doi.org/10.3109/14992027.2013.824117
https://doi.org/10.3109/14992027.2013.824117
Autor:
Signe Regner Michaelsen, Hans Skovgaard Poulsen, Ole Winther, Helle Broholm, Ulrik Lassen, Shohreh Issazadeh-Navikas, Anders Toft, Kirsten Grunnet, Thomas Urup, Michael Kosteljanetz, Ib Jarle Christensen, Lars Rønn Olsen
Publikováno v:
Urup, T, Michaelsen, S R, Olsen, L R, Toft, A, Christensen, I J, Grunnet, K, Winther, O, Broholm, H, Kosteljanetz, M, Issazadeh-Navikas, S, Poulsen, H S & Lassen, U N 2016, ' Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients ', Molecular Oncology, vol. 10, no. 8, pp. 1160-1168 . https://doi.org/10.1016/j.molonc.2016.05.005
Urup, T, Michaelsen, S R, Olsen, L R, Toft, A, Christensen, I J, Grunnet, K, Winther, O, Broholm, H, Kosteljanetz, M, Issazadeh-Navikas, S, Poulsen, H S & Lassen, U 2016, ' Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients ', Molecular Oncology, vol. 10, no. 8, pp. 1160-1168 . https://doi.org/10.1016/j.molonc.2016.05.005
Urup, T, Michaelsen, S R, Olsen, L R, Toft, A, Christensen, I J, Grunnet, K, Winther, O, Broholm, H, Kosteljanetz, M, Issazadeh-Navikas, S, Poulsen, H S & Lassen, U 2016, ' Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients ', Molecular Oncology, vol. 10, no. 8, pp. 1160-1168 . https://doi.org/10.1016/j.molonc.2016.05.005
BackgroundBevacizumab combination therapy is among the most frequently used treatments in recurrent glioblastoma and patients who achieve response to bevacizumab have improved survival as well as quality of life. Accordingly, the aim of this study wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d42e5d94bd7577a60f750cbd11fea8bc
https://curis.ku.dk/portal/da/publications/angiotensinogen-and-hla-class-ii-predict-bevacizumab-response-in-recurrent-glioblastoma-patients(b5ddaa75-9bb4-47a6-930b-7d06605e7c39).html
https://curis.ku.dk/portal/da/publications/angiotensinogen-and-hla-class-ii-predict-bevacizumab-response-in-recurrent-glioblastoma-patients(b5ddaa75-9bb4-47a6-930b-7d06605e7c39).html
Autor:
Esben Budtz-Jørgensen, Marie Louise Mølgaard Binderup, Marie Luise Bisgaard, Michael Galanakis, Michael Kosteljanetz
Publikováno v:
European journal of human genetics : EJHG. 25(3)
Von Hippel–Lindau disease (vHL) is a rare hereditary tumour predisposition with multiorgan involvement that is not always easily recognized. The disease is reported to be almost fully penetrant at age 60 years. Previous estimates of vHL prevalence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8d796f50489502043f9e552a72211cf
https://pubmed.ncbi.nlm.nih.gov/27966541
https://pubmed.ncbi.nlm.nih.gov/27966541
Autor:
Lars Poulsgaard, Jannick Brennum, Michael Kosteljanetz, Marianne Klose, Ulla Feldt-Rasmussen, Zainab Nagras
Publikováno v:
Endocrine Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5e356d8a41edb48e61d729bab89a3a88
https://doi.org/10.1530/endoabs.41.ep904
https://doi.org/10.1530/endoabs.41.ep904
Autor:
Ib Jarle Christensen, Helle Broholm, Signe Regner Michaelsen, Thomas Urup, Rikke Hedegaard Dahlrot, Steinbjørn Hansen, Anders Toft, Michael Kosteljanetz, Kirsten Grunnet, Ulrik Lassen, Hans Skovgaard Poulsen, Vibeke Andrée Larsen
Publikováno v:
Urup, T, Dahlrot, R H, Grunnet, K, Christensen, I J, Michaelsen, S R, Toft, A, Larsen, V A, Broholm, H, Kosteljanetz, M, Hansen, S, Poulsen, H S & Lassen, U 2016, ' Development and validation of a prognostic model for recurrent glioblastoma patients treated with bevacizumab and irinotecan ', Acta Oncologica, vol. 55, no. 4, pp. 418-422 . https://doi.org/10.3109/0284186X.2015.1114679
Background Predictive markers and prognostic models are required in order to individualize treatment of recurrent glioblastoma (GBM) patients. Here, we sought to identify clinical factors able to predict response and survival in recurrent GBM patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e50800861b88d6986aae2cc4c4470e3f
Autor:
Melissa L. Bondy, Christoffer Johansen, Chris Man, Beatrice Melin, Jonine L. Bernstein, Jill S. Barnholtz-Sloan, Michael Kosteljanetz, Lisa M. DeAngelis, Eastwood Leung, Christina Corpuz, Lindsay B. Robertson, Lucie McCoy, Yanhong Liu, Mark R. Gilbert, Amanda L. Rynearson, Georgina Armstrong, Roger Henriksson, Fay J. Hosking, Jeffrey S. Weinberg, Hanne Bødtcher, Lili Aslanov, Kenneth Aldape, Elli Papaemmanuil, Revital Bar Sade Bruchim, Robert Yu, Helle Broholm, Galit Hirsh Yechezkel, Dora Il'yasova, Bridget J. McCarthy, Erika Florendo, Michael E. Scheurer, Joellen M. Schildkraut, Gene Barnett, Margaret Wrensch, Karen Devine, Rose Lai, John K. Wiencke, Elizabeth B. Claus, Ulrika Andersson, Ching C. Lau, Sivashankarappa Gurusiddappa, Sanjay Shete, Ping Yang, Andrew E. Sloan, Sara H. Olson, Rita Cheng, Nicholas A. Vick, Rudy Guerra, Siegal Sadetzki, Faith G. Davis, Joseph L. Wiemels, Delcia Rivas, Thomas Brännström, Yingli Wolinsky, Caleb F. Davis, Christopher I. Amos, Erica Schubert, Robert B. Jenkins, Richard S. Houlston
Publikováno v:
Cancer Research. 71:7568-7575
Gliomas, which generally have a poor prognosis, are the most common primary malignant brain tumors in adults. Recent genome-wide association studies have shown that inherited susceptibility plays a role in the development of glioma. Although first-de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::234a9810cb0fa560a03f41d3e978ac98
https://doi.org/10.1158/0008-5472.can-11-0013
https://doi.org/10.1158/0008-5472.can-11-0013